The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Litton Mark James since 2015.
This trader's CIK number is 1604834.
At the time of last reporting, Litton Mark James was the President and CEO of Athira Pharma, Inc.. (stock ticker symbol ATHA).
Also see all insider trading activities at Athira Pharma, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2018 | ALDR | 0 | $0 | 22,727 | $408,813 | 22,727 | $22,499 |
| 2017 | ALDR | 0 | $0 | 44,053 | $635,788 | 44,053 | $70,527 |
| 2016 | ALDR | 0 | $0 | 62,000 | $1,879,910 | 75,000 | $28,874 |
| 2015 | ALDR | 0 | $0 | 55,000 | $2,150,824 | 37,764 | $25,771 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2025 | ATHA | 0 | $0 | 25,123 | $7,386 | 108,334 | $0 |
| 2024 | ATHA | 0 | $0 | 9,852 | $16,874 | 0 | $0 |
| 2022 | ATHA | 0 | $0 | 7,960 | $21,412 | 0 | $0 |
| 2021 | ATHA | 0 | $0 | 0 | $0 | 50,440 | $68,094 |
1. Alder Biopharmaceuticals Inc (ALDR)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2018-06-01 | ALDR | Sale | 22,727 | 17.99 | 408,813 |
| 2018-06-01 | ALDR | Option Ex | 22,727 | .99 | 22,499 |
| 2017-11-13 | ALDR | Sale | 16,519 | 10.80 | 178,487 |
| 2017-11-13 | ALDR | Option Ex | 16,519 | 1.65 | 27,256 |
| 2017-10-16 | ALDR | Option Ex | 16,520 | 1.65 | 27,258 |
| 2017-10-16 | ALDR | Sale | 16,520 | 12.33 | 203,708 |
| 2017-01-18 | ALDR | Option Ex | 1,498 | 1.65 | 2,471 |
| 2017-01-18 | ALDR | Sale | 1,498 | 23.10 | 34,599 |
| 2017-01-05 | ALDR | Option Ex | 2,216 | 1.26 | 2,803 |
| 2017-01-06 | ALDR | Option Ex | 6,800 | 1.46 | 9,914 |
| 2017-01-05 | ALDR | Sale | 2,216 | 23.00 | 50,972 |
| 2017-01-06 | ALDR | Sale | 6,800 | 23.02 | 156,522 |
| 2017-01-09 | ALDR | Option Ex | 500 | 1.65 | 825 |
| 2017-01-09 | ALDR | Sale | 500 | 23.00 | 11,500 |
| 2016-10-17 | ALDR | Sale | 6,000 | 27.50 | 165,000 |
| 2016-07-12 | ALDR | Option Ex | 25,000 | .39 | 9,625 |
| 2016-06-13 | ALDR | Sale | 6,000 | 29.25 | 175,524 |
| 2016-05-27 | ALDR | Option Ex | 5,280 | .39 | 2,032 |
| 2016-05-27 | ALDR | Sale | 5,280 | 30.06 | 158,695 |
| 2016-05-31 | ALDR | Option Ex | 19,720 | .39 | 7,592 |
| 2016-05-31 | ALDR | Sale | 19,720 | 30.05 | 592,566 |
| 2016-01-04 | ALDR | Sale | 25,000 | 31.52 | 788,125 |
| 2016-01-04 | ALDR | Option Ex | 25,000 | .39 | 9,625 |
| 2015-10-01 | ALDR | Sale | 7,500 | 32.52 | 243,870 |
| 2015-09-24 | ALDR | Option Ex | 12,764 | 1.26 | 16,146 |
| 2015-07-01 | ALDR | Sale | 7,500 | 51.10 | 383,220 |
| 2015-06-04 | ALDR | Option Ex | 25,000 | .39 | 9,625 |
| 2015-06-04 | ALDR | Sale | 25,000 | 44.27 | 1,106,850 |
| 2015-04-01 | ALDR | Sale | 7,500 | 27.41 | 205,552 |
| 2015-01-26 | ALDR | Sale | 5,200 | 28.02 | 145,730 |
| 2015-01-27 | ALDR | Sale | 2,300 | 28.52 | 65,602 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-06-30 | ATHA | Option Ex | 108,334 | .00 | 0 |
| 2025-07-01 | ATHA | Sale | 25,123 | .29 | 7,386 |
| 2024-09-05 | ATHA | Sale | 5,032 | .57 | 2,848 |
| 2024-01-05 | ATHA | Sale | 4,820 | 2.91 | 14,026 |
| 2022-06-23 | ATHA | Sale | 7,960 | 2.69 | 21,412 |
| 2021-08-17 | ATHA | Option Ex | 50,440 | 1.35 | 68,094 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Litton Mark James (President and CEO of Athira Pharma, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.